CN Patent

CN117379369A — 依达拉奉在制备用于治疗肌萎缩侧索硬化的口服混悬剂中的用途

Assigned to Tanabe Pharma Corp · Expires 2024-01-12 · 2y expired

What this patent protects

本申请涉及依达拉奉在制备用于治疗肌萎缩侧索硬化的口服混悬剂中的用途，其中所述混悬剂包含：依达拉奉颗粒、分散剂和水；其中(i)所述分散剂是显示1％或更高的透射散射光强度的分散剂；(ii)所述分散剂是显示80度或更小的接触角的分散剂；或者(iii)所述分散剂是选自聚乙烯醇、甲基纤维素、羟丙甲纤维素、蔗糖脂肪酸酯和聚山梨醇酯中的一种或多种。

USPTO Abstract

本申请涉及依达拉奉在制备用于治疗肌萎缩侧索硬化的口服混悬剂中的用途，其中所述混悬剂包含：依达拉奉颗粒、分散剂和水；其中(i)所述分散剂是显示1％或更高的透射散射光强度的分散剂；(ii)所述分散剂是显示80度或更小的接触角的分散剂；或者(iii)所述分散剂是选自聚乙烯醇、甲基纤维素、羟丙甲纤维素、蔗糖脂肪酸酯和聚山梨醇酯中的一种或多种。

Drugs covered by this patent

Patent Metadata

Patent number
CN117379369A
Jurisdiction
CN
Classification
—
Expires
2024-01-12
Drug substance claim
No
Drug product claim
No
Assignee
Tanabe Pharma Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.